These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32954070)

  • 1. Estimation of Changes in Kidney Volume Growth Rate in ADPKD.
    Higashihara E; Fukuhara H; Ouyang J; Lee J; Nutahara K; Tanbo M; Yamaguchi T; Taguchi S; Muto S; Kaname S; Miyazaki I; Horie S
    Kidney Int Rep; 2020 Sep; 5(9):1459-1471. PubMed ID: 32954070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
    Higashihara E; Horie S; Muto S; Kawano H; Tambo M; Yamaguchi T; Taguchi S; Kaname S; Yokoyama K; Yoshioka T; Furukawa T; Fukuhara H
    Am J Nephrol; 2020; 51(11):881-890. PubMed ID: 33227802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
    Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
    Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD.
    Higashihara E; Nutahara K; Itoh M; Okegawa T; Tambo M; Yamaguchi T; Nakamura Y; Taguchi S; Kaname S; Yokoyama K; Yoshioka T; Fukuhara H
    Kidney Int Rep; 2022 Feb; 7(2):270-281. PubMed ID: 35155866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period.
    Huh H; Kim YS; Chung W; Kim YL; Kim Y; Han S; Jung Y; Na KY; Lee KB; Oh YK; Park HC; Han SH; Yoo TH; Kim YH; Kim SW; Lee KW; Park HC; Kim SG; Kim H; Lee CH; Bae KT; Oh KH; Ahn C; Ryu HJ; Kim YC
    Kidney Res Clin Pract; 2023 Mar; 42(2):216-228. PubMed ID: 36634967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
    BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
    Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
    Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
    Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD; Torres VE;
    Nephrol Dial Transplant; 2016 Nov; 31(11):1887-1894. PubMed ID: 26681730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
    Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
    BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
    Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
    Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
    Muto S; Okada T; Shibasaki Y; Ibuki T; Horie S
    Clin Exp Nephrol; 2021 Sep; 25(9):1003-1010. PubMed ID: 34089122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
    Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
    Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Patients with End-Stage Kidney Disease in ADPKD.
    Shukoor SS; Vaughan LE; Edwards ME; Lavu S; Kline TL; Senum SR; Mkhaimer Y; Zaatari G; Irazabal MV; Neal R; Hogan MC; Zoghby ZM; Harris PC; Torres VE; Chebib FT
    Kidney Int Rep; 2021 Mar; 6(3):755-767. PubMed ID: 33732990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.